Pharma Mar (OTCMKTS:PHMMF) Trading Up 18.7% – Time to Buy?

Pharma Mar (OTCMKTS:PHMMF – Get Free Report)’s share price was up 18.7% during mid-day trading on Wednesday . The stock traded as high as $94.3374 and last traded at $94.3374. 183 shares traded hands during trading, an increase of 732% from the average session volume of 22 shares. The stock had previously closed at $79.49.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. BTIG Research initiated coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating for the company. Finally, Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Pharma Mar currently has an average rating of “Buy”.

Get Pharma Mar alerts:

Read Our Latest Stock Report on PHMMF

Pharma Mar Price Performance

The company’s 50 day moving average price is $96.52 and its 200-day moving average price is $93.78. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14.

Pharma Mar Company Profile

(Get Free Report)

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.

See Also

• Five stocks we like better than Pharma Mar
• A Market Panic Just Discounted the AI Highway’s Tollbooth
• Why Exxon Could Be the Market’s Next Big Comeback Stock
• The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
• Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.